Ikarian Capital’s Alto Neuroscience ANRO Stock Holding History

Ikarian Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7M	Sell	407,338 -107,662	-21%	-$2.49M	1.16%	26
2026 Q1	$11.6M	Hold	515,000	–	–	0.94%	27
2025 Q4	$9.17M	Buy	515,000 +405,000	+368%	+$5.1M	0.72%	38
2025 Q3	$442K	Hold	110,000	–	–	0.04%	140
2025 Q2	$242K	Sell	110,000 -65,000	-37%	-$155K	0.05%	107
2025 Q1	$378K	Sell	175,000 -175,000	-50%	-$626K	0.05%	122
2024 Q4	$1.48M	Buy	+350,000	New	+$2.18M	0.2%	92

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Ikarian Capital's ANRO Position: Q2 2026 in Review

Ikarian Capital reduced its Alto Neuroscience (ANRO) stake by 21% in Q2 2026, selling an estimated $2.49M and leaving 407,338 shares worth $10.7M. The position accounts for 1.16% of the portfolio, ranked #26.

Ikarian Capital first reported a position in ANRO in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.6M in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Ikarian Capital held 407,338 shares of Alto Neuroscience worth $10.7M as of Q2 2026.
Ikarian Capital sold 107,662 Alto Neuroscience shares in Q2 2026, an estimated $2.49M.
Alto Neuroscience made up 1.16% of Ikarian Capital's portfolio in Q2 2026, its #26 holding.
Ikarian Capital first reported a position in Alto Neuroscience in Q4 2024 and has held it in 7 quarters since.
Ikarian Capital's Alto Neuroscience position peaked at $11.6M in Q1 2026.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.